Cargando…
P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428680/ http://dx.doi.org/10.1097/01.HS9.0000969780.55126.5b |
| _version_ | 1785090526852153344 |
|---|---|
| author | Garcia-Manero, Guillermo Bachishvili, Kimo A. Griffiths, Elizabeth M. Zeidan, Amer Traer, Elie Saini, Lalit Amin, Harshad Mohan, Sanjay Lübbert, Michael Maness-Harris, Lori M Foran, James Selleslag, Dominik Xicoy Cirici, Blanca Aaron Pollyea, Daniel Sallman, David Al-Kali, Aref Berdeja, Jesus Kathrin Al-Ali, Haifa Y Zhu, Nancy Font Lopez, Patricia Sanz Santillana, Guillermo Santini, Valeria A. Yimer, Habte D Cripe, Larry Priego, Victor Odenike, Olatoyosi Heyrman, Bert Valcarcel, David Vachhani, Pankit Sano, Yuri Mirakhur, Beloo Oganesian, Aram Keer, Harold Yacoub, Abdulraheem |
| author_facet | Garcia-Manero, Guillermo Bachishvili, Kimo A. Griffiths, Elizabeth M. Zeidan, Amer Traer, Elie Saini, Lalit Amin, Harshad Mohan, Sanjay Lübbert, Michael Maness-Harris, Lori M Foran, James Selleslag, Dominik Xicoy Cirici, Blanca Aaron Pollyea, Daniel Sallman, David Al-Kali, Aref Berdeja, Jesus Kathrin Al-Ali, Haifa Y Zhu, Nancy Font Lopez, Patricia Sanz Santillana, Guillermo Santini, Valeria A. Yimer, Habte D Cripe, Larry Priego, Victor Odenike, Olatoyosi Heyrman, Bert Valcarcel, David Vachhani, Pankit Sano, Yuri Mirakhur, Beloo Oganesian, Aram Keer, Harold Yacoub, Abdulraheem |
| author_sort | Garcia-Manero, Guillermo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428680 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104286802023-08-17 P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS Garcia-Manero, Guillermo Bachishvili, Kimo A. Griffiths, Elizabeth M. Zeidan, Amer Traer, Elie Saini, Lalit Amin, Harshad Mohan, Sanjay Lübbert, Michael Maness-Harris, Lori M Foran, James Selleslag, Dominik Xicoy Cirici, Blanca Aaron Pollyea, Daniel Sallman, David Al-Kali, Aref Berdeja, Jesus Kathrin Al-Ali, Haifa Y Zhu, Nancy Font Lopez, Patricia Sanz Santillana, Guillermo Santini, Valeria A. Yimer, Habte D Cripe, Larry Priego, Victor Odenike, Olatoyosi Heyrman, Bert Valcarcel, David Vachhani, Pankit Sano, Yuri Mirakhur, Beloo Oganesian, Aram Keer, Harold Yacoub, Abdulraheem Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428680/ http://dx.doi.org/10.1097/01.HS9.0000969780.55126.5b Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Garcia-Manero, Guillermo Bachishvili, Kimo A. Griffiths, Elizabeth M. Zeidan, Amer Traer, Elie Saini, Lalit Amin, Harshad Mohan, Sanjay Lübbert, Michael Maness-Harris, Lori M Foran, James Selleslag, Dominik Xicoy Cirici, Blanca Aaron Pollyea, Daniel Sallman, David Al-Kali, Aref Berdeja, Jesus Kathrin Al-Ali, Haifa Y Zhu, Nancy Font Lopez, Patricia Sanz Santillana, Guillermo Santini, Valeria A. Yimer, Habte D Cripe, Larry Priego, Victor Odenike, Olatoyosi Heyrman, Bert Valcarcel, David Vachhani, Pankit Sano, Yuri Mirakhur, Beloo Oganesian, Aram Keer, Harold Yacoub, Abdulraheem P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS |
| title | P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS |
| title_full | P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS |
| title_fullStr | P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS |
| title_full_unstemmed | P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS |
| title_short | P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS |
| title_sort | p719: randomized phase 1-2 study to assess safety and efficacy of low-dose (ld) oral decitabine/cedazuridine (astx727) in lower-risk myelodysplastic syndromes (lr-mds) patients: interim safety analysis |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428680/ http://dx.doi.org/10.1097/01.HS9.0000969780.55126.5b |
| work_keys_str_mv | AT garciamaneroguillermo p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT bachishvilikimo p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT agriffithselizabeth p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT mzeidanamer p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT traerelie p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT sainilalit p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT aminharshad p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT mohansanjay p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT lubbertmichael p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT manessharrislori p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT mforanjames p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT selleslagdominik p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT xicoyciriciblanca p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT aaronpollyeadaniel p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT sallmandavid p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT alkaliaref p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT berdejajesus p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT kathrinalalihaifa p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT yzhunancy p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT fontlopezpatricia p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT sanzsantillanaguillermo p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT santinivaleria p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT ayimerhabte p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT dcripelarry p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT priegovictor p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT odenikeolatoyosi p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT heyrmanbert p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT valcarceldavid p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT vachhanipankit p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT sanoyuri p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT mirakhurbeloo p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT oganesianaram p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT keerharold p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis AT yacoubabdulraheem p719randomizedphase12studytoassesssafetyandefficacyoflowdoseldoraldecitabinecedazuridineastx727inlowerriskmyelodysplasticsyndromeslrmdspatientsinterimsafetyanalysis |